Ameriprise Financial Inc. Has $448,000 Stock Holdings in Benitec Biopharma Inc. (NASDAQ:BNTC)

Ameriprise Financial Inc. boosted its stake in Benitec Biopharma Inc. (NASDAQ:BNTC - Free Report) by 138.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 35,476 shares of the biotechnology company's stock after buying an additional 20,597 shares during the period. Ameriprise Financial Inc. owned 0.15% of Benitec Biopharma worth $448,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the stock. 683 Capital Management LLC bought a new position in shares of Benitec Biopharma during the fourth quarter worth about $452,000. Northern Trust Corp boosted its stake in Benitec Biopharma by 54.2% during the 4th quarter. Northern Trust Corp now owns 38,200 shares of the biotechnology company's stock valued at $482,000 after purchasing an additional 13,425 shares during the period. MYDA Advisors LLC bought a new position in Benitec Biopharma in the 4th quarter worth about $632,000. Geode Capital Management LLC grew its position in Benitec Biopharma by 134.7% in the 4th quarter. Geode Capital Management LLC now owns 197,096 shares of the biotechnology company's stock worth $2,490,000 after purchasing an additional 113,109 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. increased its stake in shares of Benitec Biopharma by 134.4% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 1,972,524 shares of the biotechnology company's stock valued at $24,913,000 after purchasing an additional 1,131,129 shares during the period. 52.19% of the stock is currently owned by institutional investors.

Benitec Biopharma Price Performance

Shares of Benitec Biopharma stock traded up $0.83 during trading on Friday, hitting $16.00. The stock had a trading volume of 63,784 shares, compared to its average volume of 41,273. The business has a fifty day moving average of $13.63 and a two-hundred day moving average of $12.41. Benitec Biopharma Inc. has a fifty-two week low of $5.74 and a fifty-two week high of $16.90. The firm has a market cap of $409.60 million, a P/E ratio of -10.60 and a beta of 0.34.

Benitec Biopharma (NASDAQ:BNTC - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($0.24) earnings per share for the quarter, beating analysts' consensus estimates of ($0.36) by $0.12. As a group, research analysts forecast that Benitec Biopharma Inc. will post -1.48 earnings per share for the current year.

Wall Street Analyst Weigh In

BNTC has been the subject of a number of recent analyst reports. JMP Securities reissued a "market outperform" rating and issued a $20.00 price objective on shares of Benitec Biopharma in a report on Thursday, May 15th. HC Wainwright reiterated a "buy" rating and set a $28.00 price target on shares of Benitec Biopharma in a research report on Monday, May 19th. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $24.71.

Insider Buying and Selling

In other news, Director Suvretta Capital Management, L bought 900,000 shares of the company's stock in a transaction dated Wednesday, March 26th. The shares were acquired at an average cost of $13.00 per share, with a total value of $11,700,000.00. Following the completion of the transaction, the director now directly owns 8,793,245 shares in the company, valued at approximately $114,312,185. The trade was a 11.40% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 1.30% of the stock is currently owned by insiders.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.